DGAP-Adhoc: Fresenius SE & Co. KGaA: Fiscal year 2013: Group net income at top end of guidance, exceeding EUR1 billion - Positive Group outlook for 2014

Fresenius SE & Co. KGaA  / Key word(s): Final Results

25.02.2014 07:00

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Fiscal year 2013: Group net income at top end of guidance, exceeding EUR1
billion - Positive Group outlook for 2014

In 2013, Group sales increased by 5% (constant currency: 8%) to EUR20,331
million (2012: EUR19,290 million. Organic sales growth was 4%. Acquisitions
contributed 5%. Divestitures reduced sales growth by 1%. Currency
translation had a negative effect of 3%.

Group EBIT* was EUR3,045 million, an increase of 1% in constant currency
(2012: EUR3,075 million). The EBIT margin was 15.0% (2012: 15.9%).

Group net income** increased by 12% (14% in constant currency) to EUR1,051
million (2012: EUR938 million). Earnings per share** increased by 8% to
EUR5.88 (2012: EUR5.42).

Group net income attributable to shareholders of Fresenius SE & Co. KGaA
including Fenwal integration costs was EUR1,011 million or EUR5.66 per
share.

Based on the strong financial results, the Management Board will propose to
the Supervisory Board a dividend increase of 14 % to EUR1.25 per share
(2012: EUR1.10). The total dividend distribution is expected to be EUR225
million.

For 2014, Fresenius projects sales growth of 12% to 15% in constant
currency. Net income*** is expected to increase by 2% to 5% in constant
currency.

The Group's U.S. GAAP financial results as of December 31, 2013 are
adjusted for Fenwal integration costs. Adjusted earnings represent the
Group's business operations in the reporting period.

 

* 2013 before Fenwal integration costs (EUR54 million); 2012 before
one-time effects

**  Net income attributable to shareholders of Fresenius SE & Co. KGaA ;
2013 before integration costs for Fenwal (EUR40 million); 2012 before
one-time effects

*** Net income attributable to shareholders of Fresenius SE & Co. KGaA;
2014 before integration costs for Fenwal (EUR30-40 million) and the
hospitals acquired from Rhön-Klinikum AG (vast majority of ~EUR65 million
in total); 2013 before Fenwal integration costs (EUR40 million)

The 2014 guidance includes contributions from the acquisition of hospitals
from Rhön-Klinikum AG.

(Financial statements according to U.S. GAAP)

Fresenius SE & Co. KGaA, 
represented by Fresenius Management SE, 
Board of Management

Bad Homburg v.d.H., February 25, 2014

End of note


25.02.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Fresenius SE & Co. KGaA
              Else-Kröner-Straße 1
              61352 Bad Homburg v.d.H.
              Germany
Phone:        +49 (0)6172 608-2485
Fax:          +49 (0)6172 608-2488
E-mail:       ir-fre@fresenius.com
Internet:     www.fresenius.com
ISIN:         DE0005785604
WKN:          578560 
Indices:      DAX
Listed:       Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard),
              München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart;
              Terminbörse EUREX
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------